|
[1]GISH RG, GIVEN BD, LAI CL, et al.Chronic hepatitis B:Virology, natural history, current management and a glimpse at future opportunities[J].Antiviral Research, 2015, 121:47-58.
|
|
[2]CHANG MH, YOU SL, CHEN CJ, et al.Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees:A 20-year follow-up study[J].J Natl Cancer Inst, 2009, 101 (19) :1348-1355.
|
|
[3]POLARIS OBSERVATORY C.Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016:A modelling study[J].Lancet Gastroenterol Hepatol, 2018, 3 (6) :383-403.
|
|
[4] YAN H, ZHONG G, XU G, et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J].Elife, 2012, 1:e00049.
|
|
[5]TRPO C, CHAN HL Y, LOK A.Hepatitis B virus infection[J].The Lancet, 2014, 384 (9959) :2053-2063.
|
|
[6]ALTER H, BLOCK T, BROWN N, et al.A research agenda for curing chronic hepatitis B virus infection[J].Hepatology, 2018, 67 (3) :1127-1131.
|
|
[7]NASSAL M.HBV cccDNA:Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J].Gut, 2015, 64 (12) :1972-1984.
|
|
[8] LUCIFORA J, XIA Y, REISINGER F, et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J].Science, 2014, 343 (6176) :1221-1228.
|
|
[9]BELLONI L, ALLWEISS L, GUERRIERI F, et al.IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J].J Clin Invest, 2012, 122 (2) :529-537.
|
|
[10]CRADICK TJ, KECK K, BRADSHAW S, et al.Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis Bvirus DNAs[J].Mol Ther, 2010, 18 (5) :947-954.
|
|
[11]WEBER ND, STONE D, SEDLAK RH, et al.AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication[J].PLo S One, 2014, 9 (5) :e97579.
|
|
[12]BLOOM K, ELY A, MUSSOLINO C, et al.Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases[J].Mol Ther, 2013, 21 (10) :1889-1897.
|
|
[13]DREYER T, NICHOLSON S, ELY A, et al.Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus[J].Biochem Bioph Res Commun, 2016, 478 (4) :1563-1568.
|
|
[14]LIN SR, YANG HC, KUO YT, et al.The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo[J].Mol Ther Nucleic Acids, 2014, 3 (2162-2531) :e186.
|
|
[15]WANG J, XU ZW, LIU S, et al.Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication[J].World JGastroenterol, 2015, 21 (32) :9554-9565.
|
|
[16]WANG J, CHEN R, ZHANG R, et al.The gRNA-miRNA-gRNA ternary cassette combining CRISPR/Cas9 with RNAi approach strongly inhibits hepatitis B virus replication[J].Theranostics, 2017, 7 (12) :3090-3105.
|
|
[17]QI YH, GAO ZC, XU GW, et al.DNA Polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus[J].PLo S Pathog, 2016, 12 (10) :e1005893.
|
|
[18]ZHANG YM, MAO RC, YAN R, et al.Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpGmethylation during chronic infection[J].PLo S One, 2014, 9 (10) :e110442.
|
|
[19]POLLICINO T, BELLONI L, RAFFA G, et al.Hepatitis B virus replication is regulated by the acetylation status of hepatitis Bvirus cccDNA-bound H3 and H4 histones[J].Gastroenterology, 2006, 130 (3) :823-837.
|
|
[20]LIU F, CAMPAGNA M, QI Y, et al.Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes[J].PLo S Pathog, 2013, 9 (9) :e1003613.
|
|
[21]ZHANG W, CHEN JL, WU M, et al.PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation[J].Hepatology, 2017, 66 (2) :398-415.
|
|
[22]WANG J.Epigenetic regulation of HBV covalently closed circular DNA:Implications for epigenetic treatment of chronic hepatitis B[J].Chin Heptol, 2018, 23 (3) :191-193. (In Chinese) 王杰.HBV共价闭合环状DNA的表观遗传调控:对慢性乙型肝炎进行表观遗传治疗的启示[J].肝脏, 2018, 23 (3) :191-193.
|
|
[23]XIA YC, STADLER D, LUCIFORA J, et al.Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis[J].Gastroenterology, 2016, 150 (1) :194-205.
|
|
[24]BOCKMANN JH, STADLER D, XIA Y, et al.Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus infected hepatocytes[J].J Infect Dis, 2019.[Epub ahead of print]
|
|
[25]QIAO Y, HAN XX, GUAN GF, et al.TGF-beta triggers HBVcccDNA degradation through AID-dependent deamination[J].Febs Letters, 2016, 590 (3) :419-427.
|
|
[26]SITTERLIN D, LEE TH, PRIGENT S, et al.Interaction of the UV-damaged DNA-binding protein with hepatitis B virus Xprotein is conserved among mammalian hepadnaviruses and restricted to transactivation-proficient X-insertion mutants[J].J Virol, 1997, 71 (8) :6194-6199.
|
|
[27]van BREUGEL PC, ROBERT EI, MUELLER H, et al.Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates[J].Hepatology, 2012, 56 (6) :2116-2124.
|
|
[28]DECORSIRE A, MUELLER H, van BREUGEL PC, et al.Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor[J].Nature, 2016, 531 (7594) :386.
|
|
[29]MURPHY CM, XU Y, LI F, et al.Hepatitis B virus X protein promotes degradation of SMC5/6 to enhance HBV replication[J].Cell Rep, 2016, 16 (11) :2846-2854.
|
|
[30]SEKIBA K, OTSUKA M, OHNO M, et al.Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBxDDB1 interaction[J].Cell Mol Gastroenterol Hepatol, 2019, 7 (2) :297-312.
|
|
[31]KO C, CHAKRABORTY A, CHOU WM, et al.Hepatitis B virus genome recycling and de novosecondary infection events maintain stable cccDNA levels[J].J Hepatol, 2018, 69 (6) :1231-1241.
|
|
[32]GUO F, ZHAO Q, SHERAZ M, et al.HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from denovo infection and intracellular amplification pathways[J].PLo S Pathog, 2017, 13 (9) :e1006658.
|
|
[33] ZHENG JW, YUAN Q, XIA NS.Progress in potential therapeutic targets and drug development for chronic hepatitis B[J/OL].Acta Microbiologica Sinica, https://doi.org/10.13343/j.cnki.wsxb.20180439. (in Chinese) 郑金伟, 袁权, 夏宁邵.慢性乙型肝炎潜在治疗靶点和新药研发进展[J/OL].微生物学报, https://doi.org/10.13343/j.cnki.wsxb.20180439.
|
DownLoad: